Company profile
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Zymeworks Delaware Inc.
SEC CIK
Corporate docs
Subsidiaries
Zymeworks CallCo ULC • Zymeworks ExchangeCo Ltd. • Zymeworks BC Inc. • Zymeworks Management Inc. • Zymeworks Biopharmaceuticals Inc. • Zymeworks Pharmaceuticals Limited • Zymeworks Lifesciences Pte. Ltd. ...
Latest filings (excl ownership)
8-K
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
18 Feb 25
8-K
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
8 Jan 25
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 24
8-K
Regulation FD Disclosure
21 Nov 24
10-Q
2024 Q3
Quarterly report
31 Oct 24
8-K
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
31 Oct 24
ARS
2023 FY
Annual report to shareholders
29 Oct 24
DEFA14A
Additional proxy soliciting materials
29 Oct 24
DEF 14A
Definitive proxy
29 Oct 24
8-K
Departure of Directors or Certain Officers
18 Oct 24
Transcripts
Earnings call transcript
2024 Q2
1 Aug 24
Earnings call transcript
2024 Q1
2 May 24
Earnings call transcript
2023 Q4
6 Mar 24
Earnings call transcript
2023 Q3
7 Nov 23
Earnings call transcript
2023 Q2
10 Aug 23
Earnings call transcript
2023 Q1
8 May 23
Earnings call transcript
2022 Q4
7 Mar 23
Earnings call transcript
2022 Q3
9 Nov 22
Latest ownership filings
SC 13D/A
EcoR1 Capital, LLC
18 Feb 25
3
OLEG NODELMAN
18 Feb 25
SC 13G/A
Redmile Group, LLC
14 Feb 25
4
Change in insider ownership
21 Jan 25
4
Change in insider ownership
15 Jan 25
SC 13D/A
EcoR1 Capital, LLC
13 Jan 25
4
Change in insider ownership
10 Jan 25
4
LEONE D PATTERSON
10 Jan 25
4
Paul Andrew Moore
10 Jan 25
4
Jeffrey T L Smith
10 Jan 25
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 122.36 mm | 122.36 mm | 122.36 mm | 122.36 mm | 122.36 mm | 122.36 mm |
Cash burn (monthly) | (no burn) | (no burn) | 11.40 mm | 11.53 mm | 1.96 mm | 4.55 mm |
Cash used (since last report) | n/a | n/a | 53.27 mm | 53.85 mm | 9.15 mm | 21.25 mm |
Cash remaining | n/a | n/a | 69.09 mm | 68.51 mm | 113.20 mm | 101.11 mm |
Runway (months of cash) | n/a | n/a | 6.1 | 5.9 | 57.8 | 22.2 |
Institutional ownership, Q3 2024
13F holders | Current |
---|---|
Total holders | 164 |
Opened positions | 27 |
Closed positions | 25 |
Increased positions | 43 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 794.00 bn |
Total shares | 73.55 mm |
Total puts | 399.80 k |
Total calls | 66.20 k |
Total put/call ratio | 6.0 |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 13.44 mm | $168.64 bn |
MS Morgan Stanley | 5.11 mm | $64.09 bn |
Redmile | 5.10 mm | $64.03 bn |
Biotechnology Value Fund L P | 4.61 mm | $0.00 |
BVF | 4.61 mm | $57.83 bn |
BlackRock | 4.26 mm | $53.51 bn |
Rubric Capital Management | 3.92 mm | $49.16 bn |
Vanguard | 2.86 mm | $35.87 bn |
All Blue Falcons FZE | 2.79 mm | $24.39 mm |
Perceptive Advisors | 2.18 mm | $27.36 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jan 25 | EcoR1 Capital | Common Stock | Buy | Acquire P | Yes | No | 13.8747 | 19,748 | 274.00 k | 15,720,161 |
16 Jan 25 | EcoR1 Capital | Common Stock | Buy | Acquire P | Yes | No | 13.885 | 121,681 | 1.69 mm | 15,700,413 |
15 Jan 25 | EcoR1 Capital | Common Stock | Buy | Acquire P | Yes | No | 14.0068 | 39,029 | 546.67 k | 15,578,732 |
14 Jan 25 | EcoR1 Capital | Common Stock | Buy | Acquire P | Yes | No | 13.5645 | 54,500 | 739.27 k | 15,539,703 |
13 Jan 25 | EcoR1 Capital | Common Stock | Buy | Acquire P | Yes | No | 13.3946 | 74,125 | 992.87 k | 15,485,203 |
10 Jan 25 | Galbraith Kenneth | RSU Common Stock | Grant | Acquire A | No | No | 0 | 192,000 | 0.00 | 192,000 |
10 Jan 25 | Galbraith Kenneth | Stock Option Common Stock | Grant | Acquire A | No | No | 13.22 | 288,000 | 3.81 mm | 288,000 |
10 Jan 25 | Jeffrey T L Smith | RSU Common Stock | Grant | Acquire A | No | No | 0 | 53,000 | 0.00 | 53,000 |
10 Jan 25 | Jeffrey T L Smith | Stock Option Common Stock | Grant | Acquire A | No | No | 13.22 | 79,000 | 1.04 mm | 79,000 |